IL28B

(redirected from interleukin 28B)

IL28B

A gene on chromosome 19q13.13 that encodes interleukin-28B, an immunomodulatory cytokine which upregulates MHC class-I antigen expression. It has potent antiviral activity and has antitumour activity. IL28B is a ligand for the heterodimeric class-II cytokine receptor composed of IL10RB and IL28RA, which is thought to act via the JAK-STAT pathway. Difference between the two isoforms of IL28 (IL28A and IL28B) remains unclear.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population.
Four genome-wide association studies (GWAS) had already associated treatment-induced clearance of HCV following PEGIFN/RBV therapy with the single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) gene on chromosome 19 [15-18].
Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients.
Interleukin 28B gene polymorphism and Association with chronic hepatitis C therapy results in Latvia.
Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children.
Role of Interleukin 28B rs12979860 C/T Polymorphism on the Histological Outcome of Chronic Hepatitis C: Relationship with Gender and Viral Genotype.
A new genetic marker, the Interleukin 28B gene, (IL28B), can predict sustained viral response to interferon-based treatment for HCV.
SAN FRANCISCO - Telaprevir is unlikely to be cost effective as a first-line agent in treatment-naive genotype 1 hepatitis C patients with the CC interleukin 28B polymorphism, according to economic modeling of previously published data.
Major Finding: Treatment-naive genotype 1 hepatitis C patients with the CC interleukin 28B polymorphism have sustained viral response rates of about 90%, regardless of whether they receive interferon, ribavirin, and telaprevir up front, or if telaprevir is used for rescue only.
(4) I would like to share the preliminary results of a larger study of the treatment of the hepatitis C virus infection in which we are investigating the role of interleukin 28B and ancestrality as predictive factors of SVR.